TRANA HUSSAİNİ, RİCKY D TURGEON, NİLUFAR PARTOVİ, SİEGFRİED R ERB, CHARLES H SCUDAMORE, ERİC M YOSHİDA
Experimental and Clinical Transplantation - 2018;16(5):550-553
Objectives: There is a clear lack of clinical evidence guiding immunosuppressive management in long-term stable liver transplant recipients. As a result, anecdotal experience suggests wide variability across transplant centers. We aimed to identify patterns of immunosuppression practices in liver transplant centers across Canada and the United States. Materials and Methods: From February 9 to May 31, 2015, we invited clinicians from all liver transplant centers in Canada and the United States to answer a 6-question survey generated using SurveyMonkey. Results: Seventeen respondents from 15 liver trans-plant centers completed the survey. Although immun-suppressive practices are relatively uniform for induction and early maintenance therapy, significant variations exist in the management of long-term immunosuppression in stable transplant recipients with a relative lack of minimization protocols. Conclusions: Our survey confirms a wide variability in immunosuppression practices across Canadian and US liver transplant centers. Research and practice priorities include design of pragmatic randomized controlled trials and development of clinical practice guidelines to standardize immunosuppressive man-agement of long-term stable liver transplant recipients with a focus on immunosuppression minimization.
